New Denodo Platform 8.0 Accelerates Hybrid/Multicloud Integration, Automates Data Management with AI/ML, and Boosts Performance
30.9.2020 09:00:00 EEST | Business Wire | Press release
Denodo, the leader in data virtualization, today announced that its new Denodo Platform version 8.0 accelerates hybrid/multicloud integration, automates data management with artificial intelligence (AI)/machine learning (ML), and boosts performance with smart query acceleration. By further augmenting the Denodo Platform’s already advanced data integration, management, and delivery capabilities with intelligent recommendations, hyper performance, and PaaS support, Denodo Platform 8.0 advances data virtualization into a logical data fabric.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005427/en/
“Data fabric is a hot, emerging market that delivers a unified, intelligent, and integrated end-to-end platform to support new and emerging use cases,” wrote Noel Yuhanna, VP and principal analyst at Forrester Research, and author of The Forrester WaveTM: Enterprise Data Fabric, Q2 2020. The report also states, “Denodo is known for data virtualization, and over the years it has also evolved into a data fabric vendor. Denodo’s data fabric solution integrates key data management components, including data integration, data ingestion, data transformation, data governance and security, to support new and emerging use cases including customers 360, real-time and on-demand analytics, IoT analytics, and self-service analytics. In addition, Denodo’s AI/ML capabilities, as well as automation, continue to enhance its capabilities across data fabric components.”
Through data virtualization, the Denodo Platform offers enterprise-grade data integration, management, and delivery that rivals legacy data integration techniques. The new version of the Denodo Platform advances agile data integration and governed data management, extending Denodo’s reach into advanced hybrid and multicloud architectures and new data science use cases.
“Denodo 8.0 packs key capabilities that are essential for our Decision Support Initiative,” said Dan Young, chief data architect and manager at Indiana University, Bloomington. “Our mission is to provide timely, relevant, and accurate data for better decision making to our executives and faculty. The Denodo Platform has been a key technology in our logical data fabric architecture, integrating student and enrollment, personnel, and financial data, and delivering the unified information to our Academics Metrics (AM) 360 dashboards. With it, decision makers at Indiana University have been able to successfully measure, compare, and analyze trends regarding the health of their responsibility centers.”
Key functionalities of Denodo Platform 8.0 include:
- Hybrid cloud/multicloud integration: Denodo Platform 8.0 enables organizations to accelerate data integration across different locations while lowering operational costs and leveraging platform-as-a-service (PaaS)-style infrastructure automation and autoscaling support.
- Machine learning/data science automation: An ML-aided data catalog helps data scientists discover and prepare data for building complex data models and aids in supporting advanced analytics. With the integrated Apache Zeppelin Notebook, they can construct narratives combining queries with code, text, and graphics, and share it with fellow data scientists.
- API/microservices enhancements: New support for execution of GraphQL on top of logical data models promotes no-code approach to the use of REST APIs and accelerates the adoption of advanced microservices architectures.
- Hyper performance: Denodo Platform 8.0 maximizes query delegation and boosts performance to sub-second responses with AI-powered recommendations, advanced caching, and smart query acceleration for frequent, expensive queries.
- Unified Web-based UI with Single Sign-On: Newly introduced interface unifies all design and runtime tools with single sign-on support facilitating rapid design, development, deployment, and management processes.
“Denodo 8.0 is the result of years of continuous innovation to support our customers’ enterprise data management journeys,” said Alberto Pan, executive vice president and chief technology officer at Denodo. “Our customers have been pioneers in their respective industries, leveraging the Denodo Platform as the enterprise logical data fabric for advanced analytics, cloud modernization, data science, and data services. We responded to our customers’ requests by providing the most advanced data platform in the industry with PaaS-style infrastructure management, machine learning data catalog, GraphQL support, smart query acceleration, and an easy-to-use unified user interface.”
Recently, Denodo was named a Leader in the 2020 Gartner Magic Quadrant for Data Integration Tools.
Please Tweet: News: @denodo announces new Denodo Platform 8.0. Latest version supports advanced #DataVirtualization #DataFabric #HybridCloud #Multicloud #ML #AI #Microservices capabilities.
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, and cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005427/en/
Contact information
Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 10:00:00 EEST | Press release
SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter timeframes. The MoU underscores growing market adoption of SWISSto12’s HummingLink payload technology that leverages 3D-printing, with more than 2,000 pr
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 10:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly effective oral therapies that also address the diverse and often challenging manifestations of psoriasis, including involvement of high-impact sites like the scalp,” said Andy Plump, M.D., Ph.D., president of R&D at Takeda. “Our Phase 3 data demonstrated rapid and durable skin clearance across various patient types and in high-impact and hard-to-treat areas. Based on the results across nearly 3,000 patients, zaso
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 10:00:00 EEST | Press release
According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, today announced the launch of Luna 8, its next-generation hardware security module. Designed for the transition to post-quantum cryptography, Luna 8 enables organizations to securely store, protect, and manage cryptographic keys with market-leading performance, scalability, and speed. As organizations face growing pressure from emerging quantum threats, expanding AI workloads and evolving stringent regulatory requirements, Luna 8 provides the performance, security and cryp
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 08:00:00 EEST | Press release
Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participants. This allows those platforms to interoperate with traditional Link-16 platfor
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom